Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al, No. 2:15-cv-01455 (E.D. Tex. Jan. 12, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court is plaintiff Allergan, Inc.’s Motion to Compel Discovery , Dkt. No. 205, which seeks to compel responses to Interrogatories Nos. 3 and 5 from defendant Mylan Pharmaceuticals, Inc., and Mylan, Inc., (“Mylan” ). The motion has been fully brief ed and was argued during a telephonic hearing conducted on January 11, 2017. The Court GRANTS the motion.